Abstract
Despite the knowledge, which has been accumulated on the central and peripheral actions of the neurokinin (NK) substance P (SP) over the last 80 years, it is only beginning to receive the attention of nuclear medicine physicians and scientists. Recently, two foci of interest have emerged: firstly, the performance of in vivo imaging studies of cerebral NK1 receptor binding with non-peptidergic NK1 receptor radioligands, and, secondly, radionuclide therapy with radiolabelled SP analogues targeting NK1 receptor binding sites. The present paper gives an overview on the utilization of nonpeptidergic and peptidergic NK1 receptor radioligands in diagnostics and therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
